DaCCoTA

Welcome to the Dakota Cancer Collaborative on Translational Activity.

What is the DaCCoTA?

daccota The goal of the DaCCoTA is to bring together researchers and clinicians with diverse experience from across the region to develop unique and innovative means of combating cancer in North and South Dakota.

We believe advances in cancer treatment will come from broad approaches by collective groups of clinical and basic researchers who are focused on conducting clinical/translational research.

The DaCCoTA is supported by the National Institute of General Medical Sciences of the National Institutes of Health under Award Number U54GM128729.

Funding Opportunities Offered Through the DaCCoTA

Community Engagement Pilot Awards

The Community Engagement Pilot Grant Awards are intended for those projects addressing priority areas as determined by key stakeholder groups including the American Cancer Society, Community Health Association of the Dakotas, ND Department of Health, and the Great Plains Tribal Chairmen’s Health Board. Proposals should address cancer disparities in either:

Colorectal cancer screening, stage and diagnosis, treatment, and mortality
Tobacco-related cancers (Lung, CRC, etc.) or
Breast cancer screening, stage at diagnosis, and mortality

RFA for Community Engagement Pilot Awards

Deadline for Assistance Finding a Collaborator: October 8, 2021
Letter of Intent Deadline: October 30, 2021
Application Deadline: January 17, 2022
Anticipated Award Period: September 2022 - August 2023

Feasibility Pilot Awards

The Feasibility Pilot Awards are designed to allow a clinician/non-clinician team to form around a novel cancer-related hypothesis. Applications can consider the multilevel manifestations of cancer (e.g. neurological, psychiatric), demographic risks and social impact. Applications should focus on T2-T4 translational research, although T1 studies will be considered if there is a clear plan to progress to T2-T4. The primary goal is to allow a team to form and connect with the CTR Biostatistics, Epidemiology, and Research Design Core; Clinical Research Resources and Facilities Core; Community Engagement and Outreach Core; and Pilot Projects Program to generate competitive proposals for the Ready-to-Go Pilot Award mechanism.

RFA for Feasibility Pilot Awards

Deadline for Assistance Finding a Collaborator: October 8, 2021
Letter of Intent Deadline: October 30, 2021
Application Deadline: January 17, 2022
Anticipated Award Period: September 2022 - August 2023

Ready-to-Go Pilot Awards

The Ready-to-Go Pilot Awards are intended for those projects with existing significant preliminary data in support of a novel clinical/translational cancer-related hypothesis. These projects should ideally be ready for extramural submission within a year and/or be able to demonstrably improve health outcomes. Applications can consider the multilevel manifestations of cancer (e.g. neurological, psychiatric), demographic risks and social impact. Applications will focus on T2-T4 translational research, although T1 studies will be considered if there is a clear plan to progress to T2-T4. Successful completion of these proposals should lead to a collaborative extramural grant submission and peer-reviewed manuscript submission.

RFA for Ready-to-Go Pilot Awards

Deadline for Assistance Finding a Collaborator: October 8, 2021
Letter of Intent Deadline: October 30, 2021
Application Deadline: January 17, 2022
Anticipated Award Period: September 2022 - August 2023

DaCCoTA Scholars Program

The purpose of this award is to stimulate the development of new Clinical and Translational Research (CTR) investigators. Applications are expected to address cancer-related CTR and can consider the multilevel manifestations of cancer (e.g. neurological, psychiatric), demographic risks, and social impact. Each awardee will receive salary support (50% FTE plus fringe) that guarantees a minimum of 50% protected research time for the project. The DaCCoTA will provide the first three years of funding, and the final two years will be funded by the applicant’s home institution (contingent on adequate progress). The awardee will also receive up to $50,000 in annual research support for up to 5 years. Individuals that have had or currently hold an NIH R01 award are not eligible for the program. Individuals who already have project funding (PI role) through an NIH IDeA program also are not eligible. A maximum budget of $160,000 is allowed, and indirect costs must be deducted from the award if the applicant’s institution warrants such removal. The DaCCoTA Scholars Program offers both a basic and community engagement track, and early career faculty are encouraged to apply.

RFA for the DaCCoTA Basic Scholars Program

Letter of Intent Deadline: October 30, 2021
Application Deadline: January 17, 2022
Anticipated Award Period: September 2022 – August 2025

RFA FOR THE DACCOTA COMMUNITY ENGAGEMENT SCHOLARS PROGRAM

Letter of Intent Deadline: October 30, 2021
Application Deadline: January 17, 2022
Anticipated Award Period: September 2022 – August 2025

Clinical Research Opportunities Program

This program provides 20% release time (up to NIH cap) to community-practicing, hospital-based clinicians to allow for participation in training activities and collaboration in cancer-focused CTR. The goal of the program is to begin to shift translational cancer research in the Upper Midwest to an enterprise informed by the patient.

The current NIH salary cap is $192,300 or $38,460 plus fringe benefits for 20% release time. Individuals may negotiate any difference between this salary amount and actual salary with their home institution. Although these awards are intended to provide 20% support for 2 years, the duration can be shortened or extended, and the % effort will be adjusted accordingly. Applications are welcome that consider the multilevel manifestations of cancer (e.g. neurological, psychiatric), demographic risks, and social impact.

It is not intended that supported individuals will become full-time, independent investigators with funding for their own research projects. However, it is expected that providing an understanding of CTR and tools for identifying unmet medical needs will allow trained clinicians to become effective collaborators. Individuals may collaborate with both clinical and non-clinical scientists to help identify unmet clinical needs that can become the focus of translational research efforts.

RFA for the Clinical Research Opportunities Program

Letter of Intent Deadline: October 30, 2021
Application Deadline: January 17, 2022
Anticipated Award Period: September 2022 – August 2024

Check back in the fall for new funding opportunities!

The DaCCoTA Pathfinder

By enrolling in the DaCCoTA Pathfinder, you will be able to search and view the research profiles of other scientists and clinicians in the DaCCoTA network to find collaborators. You will belong to a network of colleagues and collaborators with shared research interests and gain access to educational and training opportunities.

Enroll in the Pathfinder web portal to find collaborators

You will also be able to access various clinical and translational research resources including the Biostatistics, Epidemiology, and Research Design Core; the Community Engagement and Outreach Core; the Professional Development Core; the Pilot Projects Program; and the Clinical Research Resources and Facilities Core.

Explore the resources available through the DaCCoTA

Our Partners

DaCCoTA investigators may also wish to explore partnerships with the Turtle Mountain Genetics Laboratory

What is Clinical Translational Research?

Clinical/translational research (CTR) focuses on translating findings from basic research into clinical applications with the overall goal of improving the health of the community.

componentsandgoals